Abstract
Background Although intraprocedural rupture (IPR) is rare, it is a devastating complication of endovascular treatment (EVT) for intracranial aneurysms. Very few studies have been conducted on IPR, and the safety and efficacy of management techniques of IPR have not been investigated.
Methods Patients who underwent IPR during EVT between 2013 and 2022 were enrolled from the multicenter observational registry. Focusing on the management of IPR, we examined its safety and efficacy using imaging markers, including increased hemorrhage and ischemic lesions evaluated using postoperative computed tomography and diffusion-weighted imaging, respectively.
Results Of the 3269 EVT for intracranial aneurysms, 74 patients who underwent IPR (2.26%) were analyzed. Fifty-five patients (3.36%) experienced IPR in 1636 EVT cases for ruptured aneurysms. The multivariate analysis revealed that increased hemorrhage was significantly associated with poor outcomes (odds ratio [OR], 6.67 [95% confidence interval (CI), 1.07–41.44], p=0.042), whereas ischemic lesions were not. Regarding management techniques of IPR, antihypertensive medication use was significantly associated with increased hemorrhage (OR, 13.17 [95% CI, 2.26–76.69], p=0.004). Heparin reversal was an independent factor for ischemic lesions (OR, 4.81 [95% CI, 1.09–21.14], p=0.038).
Conclusions Even though the setting of IPR may be miscellaneous, and optimal management varies depending on individual cases, heparin reversal might be associated with ischemic complications rather than being useful for controlling bleeding in IPR during EVT for ruptured aneurysms.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors did not receive a specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committees of the participating institutions approved this registry (Approved number: M2020-102).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data supporting the findings of this study are available from the corresponding author upon reasonable request.
Non-standard abbreviations and acronyms
- BGC
- balloon-guiding catheter
- CI
- confidence interval
- CT
- computed tomography
- DWI
- diffusion-weighted imaging
- EVT
- endovascular treatment
- EVD
- external ventricular drainage
- HIL
- hyperintense lesion
- IPR
- intraprocedural rupture
- IQR
- interquartile range
- MRI
- magnetic resonance imaging
- mRS
- modified Rankin Scale
- OR
- odds ratio
- PAO
- parent artery occlusion
- SAH
- subarachnoid hemorrhage
- STROBE
- Strengthening the Reporting of Observational Studies in Epidemiology
- WFNS
- World Federation of Neurological Surgeons
